Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study
Background Inhibitory effects of denosumab on bone remodeling are reversible and disappear once treatment is discontinued. Herein, we examined whether and to what extent delayed denosumab administration is also associated with fracture risk using nation-wide data. Methods The study cohort included w...
Saved in:
| Main Authors: | Kyoung Min Kim, Seol A Jang, Nam Ki Hong, Chul Sik Kim, Yumie Rhee, Seok Won Park, Steven R. Cummings, Gi Hyeon Seo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Endocrine Society
2024-12-01
|
| Series: | Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.e-enm.org/upload/pdf/enm-2024-2047.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01) -
Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
by: P Madhuchandra, et al.
Published: (2024-01-01) -
EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-04-01) -
Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
by: Nihal Tezel, et al.
Published: (2021-12-01) -
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
by: Yasumori Sobue, et al.
Published: (2025-07-01)